134 related articles for article (PubMed ID: 36076121)
1. DNA ploidy and stroma predicted the risk of recurrence in low-risk stage III colorectal cancer.
Li Y; Liao L; Kong L; Jiang W; Tang J; Han K; Hou Z; Zhang C; Zhou C; Zhang L; Sui Q; Xiao B; Mei W; Xu Y; Yu J; Hong Z; Pan Z; Ding P
Clin Transl Oncol; 2023 Jan; 25(1):218-225. PubMed ID: 36076121
[TBL] [Abstract][Full Text] [Related]
2. Automated assessment of DNA ploidy, chromatin organization, and stroma fraction to predict prognosis and adjuvant therapy response in patients with stage II colorectal carcinoma.
Zhao Z; Zhang X; Li Z; Gao Y; Guan X; Jiang Z; Liu Z; Yang M; Chen H; Ma X; Yang R; Lu Z; Liu H; Yang L; Wu A; Zou S; Wang X
Am J Cancer Res; 2021; 11(12):6119-6132. PubMed ID: 35018246
[TBL] [Abstract][Full Text] [Related]
3. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
[TBL] [Abstract][Full Text] [Related]
4. Underutilization or appropriate care? Assessing adjuvant chemotherapy use and survival in 3 heterogenous subpopulations with stage II/III colorectal cancer within a large integrated health system.
Chen Y; Shankaran V; Hahn EE; Haupt EC; Bansal A
J Manag Care Spec Pharm; 2023 Jun; 29(6):635-646. PubMed ID: 37276035
[No Abstract] [Full Text] [Related]
5. Prognostic markers for colorectal cancer: estimating ploidy and stroma.
Danielsen HE; Hveem TS; Domingo E; Pradhan M; Kleppe A; Syvertsen RA; Kostolomov I; Nesheim JA; Askautrud HA; Nesbakken A; Lothe RA; Svindland A; Shepherd N; Novelli M; Johnstone E; Tomlinson I; Kerr R; Kerr DJ
Ann Oncol; 2018 Mar; 29(3):616-623. PubMed ID: 29293881
[TBL] [Abstract][Full Text] [Related]
6. ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy.
Li P; Fang YJ; Li F; Ou QJ; Chen G; Ma G
Br J Cancer; 2013 Apr; 108(6):1238-44. PubMed ID: 23481186
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
9. Effects of deficient mismatch repair on the prognosis of patients with stage II and stage III colon cancer during different postoperative periods.
Zhang C; Zhan Y; Ni K; Liu Z; Xin R; Han Q; Li G; Ping H; Liu Y; Zhao X; Wang W; Yan S; Sun J; Zhang Q; Wang G; Zhang Z; Zhang X; Hu X
BMC Cancer; 2022 Nov; 22(1):1156. PubMed ID: 36352365
[TBL] [Abstract][Full Text] [Related]
10. Combining pathological risk factors and T, N staging to optimize the assessment for risk stratification and prognostication in low-risk stage III colon cancer.
Xian ZY; Song YW; Zhang ZJ; Gan YG; Chen YL; Hu T; Wen XF; Mo TW; He XW
World J Surg Oncol; 2024 Jan; 22(1):10. PubMed ID: 38178080
[TBL] [Abstract][Full Text] [Related]
11. [Relationship between the expression of DDX39 protein and prognosis of colorectal cancer].
Ma J; Chang W; Zhang W
Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Mar; 21(3):336-341. PubMed ID: 29577224
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive role of DNA mismatch repair status in stage II-III colorectal cancer: A systematic review and meta-analysis.
Deng Z; Qin Y; Wang J; Wang G; Lang X; Jiang J; Xie K; Zhang W; Xu H; Shu Y; Zhang Y
Clin Genet; 2020 Jan; 97(1):25-38. PubMed ID: 31432497
[TBL] [Abstract][Full Text] [Related]
13. Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials.
Sinicrope FA; Foster NR; Yoon HH; Smyrk TC; Kim GP; Allegra CJ; Yothers G; Nikcevich DA; Sargent DJ
J Clin Oncol; 2012 Feb; 30(4):406-12. PubMed ID: 22203756
[TBL] [Abstract][Full Text] [Related]
14. Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer.
Korphaisarn K; Pongpaibul A; Limwongse C; Roothumnong E; Klaisuban W; Nimmannit A; Jinawath A; Akewanlop C
World J Gastroenterol; 2015 Jan; 21(3):926-34. PubMed ID: 25624727
[TBL] [Abstract][Full Text] [Related]
15. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study.
Tougeron D; Mouillet G; Trouilloud I; Lecomte T; Coriat R; Aparicio T; Des Guetz G; Lécaille C; Artru P; Sickersen G; Cauchin E; Sefrioui D; Boussaha T; Ferru A; Matysiak-Budnik T; Silvain C; Karayan-Tapon L; Pagès JC; Vernerey D; Bonnetain F; Michel P; Taïeb J; Zaanan A
J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26839356
[TBL] [Abstract][Full Text] [Related]
17. [Correlations between DNA mismatch repair (MMR) and prognosis and prediction of treatment efficacy in stage II/II colon cancer].
Qin Q; Ying J; Lyu N; Guo L; Zhi W; Zhou A; Wang J
Zhonghua Zhong Liu Za Zhi; 2014 Nov; 36(11):844-8. PubMed ID: 25620482
[TBL] [Abstract][Full Text] [Related]
18. The association between neutropenia and prognosis in stage III colorectal cancer patients receiving adjuvant chemotherapy.
Sunaga T; Suzuki S; Kogo M; Kurihara T; Kaji S; Koike N; Harada N; Suzuki M; Kiuchi Y
Eur J Cancer Care (Engl); 2014 May; 23(3):394-400. PubMed ID: 24033646
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.
Sinicrope FA; Mahoney MR; Smyrk TC; Thibodeau SN; Warren RS; Bertagnolli MM; Nelson GD; Goldberg RM; Sargent DJ; Alberts SR
J Clin Oncol; 2013 Oct; 31(29):3664-72. PubMed ID: 24019539
[TBL] [Abstract][Full Text] [Related]
20. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
Zaanan A; Shi Q; Taieb J; Alberts SR; Meyers JP; Smyrk TC; Julie C; Zawadi A; Tabernero J; Mini E; Goldberg RM; Folprecht G; Van Laethem JL; Le Malicot K; Sargent DJ; Laurent-Puig P; Sinicrope FA
JAMA Oncol; 2018 Mar; 4(3):379-383. PubMed ID: 28983557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
